Poxel Announces the Grant of Patent in China Protecting the Use of Imeglimin for Type-2 Diabetic Patients with Renal Impairment Jan 20, 2025
Poxel to receive sales-based payment and higher level of royalties from Sumitomo Pharma in Q1 2025 for TWYMEEG® Achieving JPY 5 billion Net Sales in Japan Jan 20, 2025
Poxel Reports Financial Results for First Half 2024 and Provides an Update on its Financial Position and Outlook Dec 9, 2024
Poxel Announces that its Annual General Meeting Will Be Held on November 28, 2024, at 9 am CET and the Availability of Preparatory Documents Nov 7, 2024
Poxel Reports Cash and Revenue for the Third Quarter and Nine Months 2024 and Provides Corporate Update Nov 6, 2024
